Adial Pharmaceuticals, Inc. last reported quarterly results on Aug 17, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$11.25. It usually reports 41–65 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–65 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 17, 2026
48 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-52
-2555.2%
|
-11.25
-144.0%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-2
+9.2%
|
-1.48
+82.6%
|
|
Mar 6, 2026
65 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-2
+3.6%
|
0.05
-67.9%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-2
+18.2%
|
-0.08
+78.9%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-2
+20.4%
|
-4.61
-681.4%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-2
|
-8.52
|
|
Mar 4, 2025
63 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-2
-7.8%
|
0.17
+120.7%
|
|
Nov 14, 2023
45 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZR (Nasdaq), ADIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1513525
- Former names
- ADIAL PHARMACEUTICALS, INC. (until Oct 30, 2026); Adial Pharmaceuticals, L.L.C. (until Sep 28, 2017); ADial Pharmaceuticals, L.L.C. (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.